Nektar Therapeutics (NASDAQ: NKTR) on Monday, plunged -8.62% from the previous trading day, before settling in for the closing price of $0.75. Within the past 52 weeks, NKTR’s price has moved between $0.43 and $1.93.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -0.50% over the last five years. The company achieved an average annual earnings per share of -14.08%. With a float of $179.37 million, this company’s outstanding shares have now reached $185.78 million.
The firm has a total of 61 workers. Let’s measure their productivity. In terms of profitability, gross margin is 68.82%, operating margin of -92.39%, and the pretax margin is -121.1%.
Nektar Therapeutics (NKTR) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Nektar Therapeutics is 3.62%, while institutional ownership is 69.04%. The most recent insider transaction that took place on Feb 19 ’25, was worth 10,403. In this transaction Chief R&D Officer of this company sold 10,300 shares at a rate of $1.01, taking the stock ownership to the 316,604 shares. Before that another transaction happened on Feb 19 ’25, when Company’s Chief Legal Officer sold 11,040 for $1.01, making the entire transaction worth $11,150. This insider now owns 324,292 shares in total.
Nektar Therapeutics (NKTR) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.18 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -14.08% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -15.48% during the next five years compared to 25.49% growth over the previous five years of trading.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
Nektar Therapeutics (NKTR) is currently performing well based on its current performance indicators. A quick ratio of 4.26 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.58, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.80 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
Analysing the last 5-days average volume posted by the [Nektar Therapeutics, NKTR], we can find that recorded value of 1.64 million was lower than the volume posted last year of 2.23 million. As of the previous 9 days, the stock’s Stochastic %D was 50.95%. Additionally, its Average True Range was 0.07.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 31.37%, which indicates a significant decrease from 41.30% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.28% in the past 14 days, which was lower than the 90.77% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7437, while its 200-day Moving Average is $1.0425. Now, the first resistance to watch is $0.7391. This is followed by the second major resistance level at $0.7911. The third major resistance level sits at $0.8206. If the price goes on to break the first support level at $0.6576, it is likely to go to the next support level at $0.6281. Should the price break the second support level, the third support level stands at $0.5761.
Nektar Therapeutics (NASDAQ: NKTR) Key Stats
Market capitalization of the company is 127.89 million based on 186,104K outstanding shares. Right now, sales total 98,430 K and income totals -118,960 K. The company made 29,180 K in profit during its latest quarter, and 7,260 K in sales during its previous quarter.
